{"title":"Performance","description":"\u003cp class=\"font-claude-response-body\"\u003e\u003cspan style=\"font-family: 'Arial',sans-serif;\"\u003eThis collection brings together the best peptides for performance research available in our Canadian catalog — compounds with documented preclinical and clinical activity across the GH\/IGF-1 axis, melanocortin pathways, and sexual response circuitry.\u003c\/span\u003e\u003c\/p\u003e","products":[{"product_id":"buy-melanotan-2-canada","title":"Melanotan II (MT-2)","description":"\u003ch2\u003e\u003cb\u003eBuy Melanotan 2 Canada — Synthetic α-MSH Analog\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy Melanotan 2 in Canada as a research-grade synthetic melanocortin agonist for pigmentation, appetite, and sexual response research designs. Melanotan 2 (MT-2) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), originally developed at the University of Arizona in the 1980s. The compound acts as a non-selective agonist across multiple melanocortin receptors (MC1R through MC5R), giving research designs broad pharmacological access to melanocortin biology. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₅₀H₆₉N₁₅O₉ \/ 1024.18 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 121062-08-6\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes Melanotan 2 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eMelanotan 2 was developed at the University of Arizona by Victor Hruby and colleagues in the late 1980s as part of a structure-activity program designed to produce metabolically stable α-MSH analogs. The key innovations — replacement of methionine with norleucine, substitution of L-phenylalanine with its D-enantiomer, and lactamization between aspartic acid and lysine to lock the peptide into its bioactive conformation — produced a compound with substantially extended half-life and full agonist activity at multiple melanocortin receptors.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes Melanotan 2 from later melanocortin tools is its broad receptor profile. Where bremelanotide (PT-141) shows preferential activity at MC4R, Melanotan 2 acts as a non-selective agonist across MC1R, MC3R, MC4R, and MC5R — making it a useful reference compound for groups dissecting receptor-specific contributions to melanocortin pathway phenotypes.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003ePigmentation \u0026amp; Melanogenesis —\u003c\/b\u003e MC1R activation in melanocyte models drives eumelanin synthesis through cAMP-PKA-MITF signaling. Published cell and animal studies have measured dose-dependent increases in melanin content following Melanotan 2 exposure, supporting its use as a reference tool in pigmentation research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAppetite \u0026amp; Energy Balance —\u003c\/b\u003e Hypothalamic MC3R and MC4R activation has been studied for its role in feeding suppression. Rodent models have reported reduced food intake across multiple hyperphagia paradigms following intracerebroventricular Melanotan 2 administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMelanocortin Receptor Pharmacology —\u003c\/b\u003e As a non-selective full agonist, Melanotan 2 serves as a baseline tool compound in receptor-deconvolution studies where researchers compare its profile against subtype-selective agonists and antagonists.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eUV Photoprotection Research —\u003c\/b\u003e Eumelanin produced via MC1R activation absorbs UV radiation, and Melanotan 2 has been investigated in animal models as a tool for studying tan-mediated photoprotection independent of UV exposure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSexual Response Circuitry —\u003c\/b\u003e MC3R\/MC4R activation in CNS pathways has been examined in animal models of sexual response, with Melanotan 2 preceding the development of more receptor-selective compounds in this research area.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with Melanotan 2 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/pt-141\" title=\"View PT-141 Product Page\"\u003ePT-141\u003c\/a\u003e\u003c\/b\u003e — Bremelanotide, an MC3R\/MC4R-preferring melanocortin agonist; the standard mechanistic contrast for Melanotan 2 in receptor-selectivity studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\" title=\"View GHK-Cu Product Page\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Copper tripeptide investigated for ECM remodeling and skin biology; complements Melanotan 2's pigmentation focus with a separate copper-mediated dermal-research angle.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"file:\/\/\/products\/buy-bpc-157\" title=\"View BPC-157 Product Page\"\u003eBPC-157\u003c\/a\u003e\u003c\/b\u003e — Pentadecapeptide studied for cytoprotection and tissue repair; pairs with Melanotan 2 in dermal-research designs spanning pigmentation and repair endpoints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy Melanotan 2 in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur Melanotan 2 ships to Canadian research labs and independent investigators with a batch-specific certificate of analysis confirming ≥99% HPLC purity and mass-spec identity verification. Vials are filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and ship from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is Melanotan 2 different from PT-141?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are α-MSH-derived melanocortin agonists, but they differ in receptor selectivity. Melanotan 2 is a non-selective full agonist across MC1R, MC3R, MC4R, and MC5R, making it active in pigmentation, appetite, and sexual-response research. PT-141 (bremelanotide) shows preferential activity at MC3R and MC4R, with reduced MC1R engagement, which is why it became the focus of CNS-mediated sexual response research while Melanotan 2 remained a broader pigmentation and melanocortin-pathway tool.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs Melanotan 2 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eNo. Melanotan 2 is a synthetic cyclic heptapeptide engineered as a stable analog of α-MSH, the natural melanocortin hormone that consists of a 13-amino-acid linear sequence. The structural modifications — D-phenylalanine substitution, norleucine for methionine, and the Asp-Lys lactam bridge — are deliberately non-natural and confer the metabolic stability that endogenous α-MSH lacks.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for Melanotan 2?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe published preclinical literature spans more than three decades, beginning with foundational structure-activity work from Hruby and colleagues at the University of Arizona in the late 1980s and 1990s. Subsequent cell and animal studies have characterized melanogenesis, appetite, and CNS effects across multiple model systems. Pilot human clinical data exist but Melanotan 2 has not received approval from any major regulatory agency for human use.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️\u003cem\u003e For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745407656073,"sku":null,"price":44.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":45745407688841,"sku":null,"price":259.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":45745407721609,"sku":null,"price":399.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/melanotan-II-MT-2-10mg-peptide-canada_standardized_147a9c06-3f6e-4f61-ae0d-378bf259f4fc.png?v=1778370884"},{"product_id":"buy-tesamorelin-canada","title":"Tesamorelin","description":"\u003ch2\u003e\u003cb\u003eBuy Tesamorelin Canada — Synthetic GHRH(1-44) Analog\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy Tesamorelin in Canada as a research-grade GHRH analog for somatotropic axis, lean mass, and visceral adiposity research designs. Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), engineered with an N-terminal trans-3-hexenoic acid modification that confers resistance to DPP-IV cleavage. Developed by Montreal-based Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta for visceral adiposity in HIV-associated lipodystrophy, Tesamorelin remains the only GHRH analog to receive regulatory approval. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₂₂₁H₃₆₆N₇₂O₆₇S \/ ~5135.9 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 218949-48-5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes Tesamorelin a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eTesamorelin was developed by Theratechnologies, Inc., a Montreal-based biotech, and remains the only GHRH analog to receive FDA approval — granted in 2010 for visceral adiposity reduction in HIV-associated lipodystrophy under the brand name Egrifta. That clinical track gives researchers a published human pharmacokinetic, pharmacodynamic, and safety dataset most research peptides cannot match.\u003c\/p\u003e\n\u003cp\u003eStructurally, Tesamorelin retains the full 44-amino-acid hGHRH sequence, distinguishing it from shorter GHRH fragments like sermorelin (GHRH 1-29). The trans-3-hexenoic acid moiety attached to the N-terminal tyrosine extends half-life by blocking DPP-IV cleavage at the Tyr¹-Ala² bond, the primary degradation site for native GHRH. Among Canadian research compounds with a documented clinical trail, Tesamorelin sits in a small group of GHRH-axis tools available for laboratory investigation.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eGH\/IGF-1 Axis Activation —\u003c\/b\u003e Tesamorelin elicits pulsatile GH secretion through GHRHR agonism, with downstream IGF-1 elevation observed across published preclinical and clinical pharmacodynamic studies — making it a reference tool for somatotropic-axis investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLean Mass \u0026amp; Anabolic Research —\u003c\/b\u003e GH and IGF-1 elevation drive protein synthesis and skeletal muscle anabolism in published animal models, supporting Tesamorelin's use in research designs comparing GH-axis activation against alternative anabolic peptide mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eVisceral Adiposity —\u003c\/b\u003e Phase 3 clinical trials demonstrated dose-dependent reductions in visceral adipose tissue, mediated through GH-stimulated hormone-sensitive lipase activity. The dataset gives researchers a uniquely well-characterized human reference for GH-driven lipolysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLipid Metabolism \u0026amp; Cardiometabolic Markers —\u003c\/b\u003e Published trials have measured improvements in triglyceride profiles and adiponectin alongside VAT reduction, generating sustained interest in Tesamorelin as a tool for cardiometabolic-pathway research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCognitive Aging Research —\u003c\/b\u003e Randomized studies have explored Tesamorelin's effects on cognitive markers and brain GABA\/myo-inositol ratios in older adults, opening a parallel research direction beyond its primary metabolic indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with Tesamorelin often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-retatrutide-canada\" title=\"View Retatrutide Product Page\"\u003eRetatrutide\u003c\/a\u003e\u003c\/b\u003e — Triple GLP-1\/GIP\/glucagon agonist; provides a clean mechanistic contrast to GH-axis-driven body composition effects in metabolic-research designs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\" title=\"View MOTS-c Product Page\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Mitochondria-derived peptide investigated for insulin sensitivity and exercise-mimetic activity; complements Tesamorelin's endocrine angle with cellular-energetics research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-bpc-157\" title=\"View BPC-157 Product Page\"\u003eBPC-157\u003c\/a\u003e\u003c\/b\u003e — Pentadecapeptide studied for tissue repair and cytoprotection; pairs with Tesamorelin in research designs combining anabolic signaling and recovery endpoints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy Tesamorelin in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur Tesamorelin ships to Canadian research labs and independent investigators with a batch-specific certificate of analysis confirming ≥99% HPLC purity and mass-spec identity verification. Vials are filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and ship from within Canada to avoid border-related cold-chain interruptions. Tesamorelin was originally developed in Canada by Theratechnologies, giving it a notable connection to Canadian peptide research.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is Tesamorelin different from sermorelin or CJC-1295?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eSermorelin is a truncated GHRH(1-29) fragment with a much shorter half-life. CJC-1295 is also based on GHRH(1-29) but adds amino acid substitutions (and, in DAC variants, a maleimidopropionic acid linker for albumin binding). Tesamorelin retains the full GHRH(1-44) sequence with N-terminal lipid modification, giving it both DPP-IV resistance and the full receptor-binding domain of native GHRH — a different structural strategy from the truncated analogs.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs Tesamorelin naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePartially. The 44-amino-acid sequence corresponds to native human GHRH, an endogenous hypothalamic peptide. The N-terminal trans-3-hexenoic acid modification is synthetic and does not occur in nature; it is added specifically to extend metabolic stability for research and clinical use.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for Tesamorelin?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eTesamorelin has the most developed evidence base of any GHRH analog. Phase 3 clinical trials in HIV-associated lipodystrophy supported its 2010 FDA approval, with published data on visceral fat reduction, IGF-1 elevation, lipid profiles, and tolerability. Subsequent research has examined cognitive aging, NAFLD, and broader metabolic endpoints.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745412472969,"sku":null,"price":84.99,"currency_code":"CAD","in_stock":true},{"title":"6x10mg","offer_id":45745412505737,"sku":null,"price":489.99,"currency_code":"CAD","in_stock":true},{"title":"10x10mg (one box)","offer_id":45745412538505,"sku":null,"price":749.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/tesamorelin-10mg-peptide-canada_standardized.png?v=1778370746"},{"product_id":"pt-141","title":"PT-141","description":"\u003ch2\u003e\u003cb\u003ePT-141 — Melanocortin Receptor Agonist\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy PT-141 in Canada as a research-grade melanocortin receptor agonist for CNS sexual response, neuropharmacology, and MC3R\/MC4R research designs. PT-141 (also known by the international nonproprietary name bremelanotide) is a synthetic cyclic heptapeptide originally derived from Melanotan II, developed by Palatin Technologies and approved by the FDA in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eProduct Details\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₅₀H₆₈N₁₄O₁₀ \/ 1025.2 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 189691-06-3\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes PT-141 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003ePT-141 traces its origin to the University of Arizona melanocortin research program led by Victor Hruby and Mac Hadley, where structure-activity work on Melanotan 2 produced the now well-known observation that broad-spectrum melanocortin agonism engaged not only pigmentation pathways but also CNS-mediated sexual response circuitry. Palatin Technologies subsequently developed PT-141 (bremelanotide) as a more receptor-selective compound that preserved the CNS activity while attenuating peripheral melanocortin engagement.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes PT-141 in current research is its regulatory status. In June 2019, the FDA approved bremelanotide under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it the only peptide-based melanocortin agonist with full FDA clinical validation in this domain. That approval gives researchers a published Phase 3 dataset, characterized human pharmacokinetics, and a defined mechanism — properties most research peptides lack. Its action is mediated centrally via hypothalamic melanocortin receptors, distinguishing it mechanistically from peripheral vasodilator approaches to sexual dysfunction research.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eCNS-Mediated Sexual Response —\u003c\/b\u003e Animal and clinical studies have characterized PT-141's activation of hypothalamic MC3R and MC4R as the basis for downstream effects on sexual desire and arousal circuitry, distinguishing it from peripheral vasodilator compounds in mechanistic research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMelanocortin Receptor Pharmacology —\u003c\/b\u003e PT-141 serves as a reference MC3R\/MC4R-preferring agonist in receptor-deconvolution studies, frequently compared against non-selective tools like Melanotan 2 to dissect receptor-subtype contributions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAppetite \u0026amp; Energy Balance —\u003c\/b\u003e Hypothalamic MC4R activation has been studied in animal models for its role in feeding suppression, and PT-141 contributes to the published dataset on MC4R-mediated satiety signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePharmacokinetic Characterization —\u003c\/b\u003e As one of few melanocortin peptides with detailed published clinical pharmacokinetic data, PT-141 functions as a reference compound for groups studying cyclic-heptapeptide ADME profiles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eComparator in Sexual Function Research —\u003c\/b\u003e PT-141's centrally mediated mechanism makes it a frequently used comparator in research designs evaluating peptide-based versus small-molecule approaches to sexual response pathway investigation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with PT-141 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca title=\"View Melanotin II Product Page\" href=\"https:\/\/emeraldpeptides.ca\/products\/buy-melanotan-2-canada\"\u003eMelanotan II (MT-2)\u003c\/a\u003e\u003c\/b\u003e — The non-selective parent compound from which PT-141 is derived; the standard mechanistic contrast for receptor-selectivity studies and one of the most common research pairings in the published melanocortin literature.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca title=\"View Tesamorelin Product Page\" href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GHRH analog acting on hypothalamic-pituitary signaling; provides a complementary mechanism for groups studying peptide-mediated CNS-endocrine pathway activity alongside melanocortin research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca title=\"View GHK-Cu Product Page\" href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Copper tripeptide investigated for skin and ECM remodeling; pairs with PT-141 in research designs spanning the skin-and-sexual-health endpoints common in melanocortin-system studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhy is PT-141 frequently described as a best peptide for male potential increase research?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePT-141 is the most clinically validated research peptide acting on CNS-mediated sexual response pathways. It engages MC3R and MC4R in hypothalamic circuits associated with sexual desire and arousal, mechanistically distinct from peripheral vasodilator compounds like PDE5 inhibitors. The compound completed Phase 3 clinical trials under the brand name Vyleesi and received FDA approval in 2019 for hypoactive sexual desire disorder. That published dataset, combined with a defined receptor-selectivity profile, places it among the most studied research peptides in male and female sexual response models.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is PT-141 different from Melanotan 2?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are cyclic heptapeptide α-MSH analogs with the same seven-amino-acid sequence. The single structural difference is at the C-terminus: PT-141 ends in a carboxylic acid (-OH), while Melanotan 2 ends in an amide (-NH₂). PT-141 is the active metabolite of Melanotan 2 in vivo. Functionally, the substitution shifts receptor selectivity toward MC3R and MC4R while reducing MC1R engagement, meaning PT-141 retains the CNS-mediated sexual response profile while showing diminished pigmentation activity compared to its parent.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs PT-141 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eNo. PT-141 is fully synthetic, engineered as a stable cyclic analog of α-MSH, the natural 13-amino-acid melanocortin hormone. The structural modifications — D-phenylalanine substitution, norleucine for methionine, and the Asp-Lys lactam bridge — are non-natural and confer the metabolic stability that endogenous α-MSH lacks.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for PT-141?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePT-141 has one of the most developed evidence bases of any research-relevant melanocortin peptide. Phase 3 clinical trials in premenopausal women with hypoactive sexual desire disorder supported its 2019 FDA approval under the brand name Vyleesi. The preclinical literature spans more than two decades and includes published work in male and female sexual response, melanocortin receptor pharmacology, and pharmacokinetic characterization. Earlier-stage clinical work in male erectile dysfunction was also conducted, providing additional published data points.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":46052264247433,"sku":null,"price":44.99,"currency_code":"CAD","in_stock":false},{"title":"6 x 10mg","offer_id":46052264280201,"sku":null,"price":259.99,"currency_code":"CAD","in_stock":false},{"title":"10 x 10mg (one box)","offer_id":46134036332681,"sku":null,"price":399.99,"currency_code":"CAD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/pt-141-10mg-peptides-canada_standardized.png?v=1778371603"}],"url":"https:\/\/emeraldpeptides.ca\/collections\/best-peptides-for-performance.oembed","provider":"Emerald Peptides","version":"1.0","type":"link"}